Skip to main content
. 2022 Jan 26;9(2):122–131. doi: 10.1002/acn3.51492

Figure 1.

Figure 1

Flowchart shows patients included in the study, immunological characteristics, number of drug‐refractory patients and outcome. MG, myasthenia gravis; anti‐AChR, anti‐acetylcholine receptor; anti‐MuSK, anti‐muscle‐specific tyrosine kinase; MM, minimal manifestations; I, improvement; U, unchanged; W, worsening. [Colour figure can be viewed at wileyonlinelibrary.com]